Coverage Initiated: September 2004

Corcept Therapeutics (CORT) is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Its lead product candidate, Corlux, is aimed at treating psychotic depression and Cushing’s syndrome.

A complete listing of our research on Corcept Therapeutics is available by clicking here.